Pharma shares in demand; Healthcare index hits new high

Sun Pharma, Ranbaxy, Dr Reddy's Lab, Lupin, Glenmark, Wockhardt and Cadila Healtchare gained 1-8% on BSE.

SI Reporter Mumbai
Last Updated : Jul 25 2014 | 2:27 PM IST
Shares of frontline pharmaceutical companies are in demand on the bourses with the BSE Healthcare index hitting new high in an otherwise weak market today.

S&P Healthcare index, gauge of pharmaceutical companies, has surged 1% or 130 points compared to nearly 1% or 185 points decline in benchmark S&P BSE Sensex at 1400 hours. The healthcare index hit a record high of 12,070 in intra-day.

Sun Pharmaceutical Industries, Ranbaxy Laboratories, Dr Reddy’s Laboratories, Lupin, Glenmark Pharmaceuticals, Wockhardt, Cadila Healtchare and Cipla gained between 1% and 8% on the BSE.

Sun Pharma (up 3% at Rs 772) and Lupin (up 2.5% at Rs 1,122) hit their respective new highs on BSE.

Ranbaxy has surged 3% to Rs 579, also its fresh 52-week high after the company said it has signed a licensing agreement with Canada’s Cipher Pharmaceuticals Inc to exclusively market, sell and distribute Cipher’s isotretinoin capsules in Brazil.

The agreement extends the current relationship with Cipher, under which Ranbaxy is marketing and distributing Cipher’s isotretinoin product in the US under the brand Absorica.

Glenmark Pharmaceuticals has rallied 6% to Rs 633 on reporting a strong 44% year-on-year jump in consolidated profit at Rs 185 crore on back of strong revenue growth for the quarter ended June 2014. The company had profit of Rs 129 crore in year ago quarter.

For the first quarter ended June 30, 2014, Glenmark’s consolidated revenue was at Rs 1,487 crore as against Rs 1,238 crore in the corresponding quarter recording a growth of 20%. EBITDA or operating profit margins improved 300 basis points to 23% from 20%.

Wockhardt zoomed 8% to Rs 711 on back of over four-fold jump in trading volumes. The stock opened at Rs 666 and touched a high of Rs 720 on BSE. A combined 8.95 million shares changed hands on the counter till 1410 hours on NSE and BSE. In past one week, the stock rallied 21% compared to 1.7% rise in the benchmark index.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 25 2014 | 2:19 PM IST

Next Story